Bedding materials and early infant wheezing: A randomised controlled trial

Caroline Halley1, Janice Kang1, Phillipa Barnes1

  • 1Department of Medicine, University of Otago Wellington, Wellington, New Zealand.

Insights

This randomized trial found no difference in wheezing for infants using synthetic, wool, or feather bedding. Parental avoidance of feather bedding in at-risk children may explain previous observational study findings.

Area of Science:

  • Pediatrics
  • Environmental Health
  • Allergy and Immunology

Background:

  • Observational studies suggest a link between bedding materials and childhood wheezing.
  • Synthetic bedding is associated with increased wheezing, while feather bedding is linked to decreased wheezing.

Purpose of the Study:

  • To test the hypothesis that feather bedding reduces wheezing in infants.
  • To investigate the impact of synthetic, wool, and feather bedding on respiratory health in early childhood.

Main Methods:

  • A three-armed, parallel, randomized trial involving 460 infants in Wellington, New Zealand.
  • Infants were assigned synthetic, wool, or feather sleepsacks from 3 months to 2 years of age.
  • Wheezing, respiratory parameters, and atopic status were assessed at 2 years.

Main Results:

  • No significant differences in reported or doctor-diagnosed wheezing were found across bedding material groups.
  • A significantly increased rate of wheezing presentation at GP surgery was observed for children using feather materials compared to synthetic (RR 2.00, 95% CI: 1.14, 3.52).

Conclusions:

  • The study does not support previous observational findings linking synthetic bedding to higher wheezing rates or feather bedding to lower rates in early childhood.
  • Selection bias, where parents of at-risk children avoid feather bedding, may explain the discrepancy with observational studies.
Abstract

Related Concept Videos

Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
186